Immunic Inc. Stock News

Immunic Inc (NASDAQ:IMUX) has published extended data from its Phase 2 EMPhASIS trial of its lead asset vidofludimus calcium in relapsing-remitting Multiple Sclerosis (RRMS) in the peer-reviewed journ

Immunic Inc (NASDAQ:IMUX) has received a Notice of Allowance for a composition-of-matter patent covering a specific polymorph of vidofludimus calcium, which is being advanced as a treatment for chroni

Immunic Inc (NASDAQ:IMUX) announced that it will present data from its Phase 2 CALLIPER and CALVID-1 clinical trials of its lead asset vidofludimus calcium (IMU-838) at the Americas Committee for Trea

Biotechnology company Immunic Inc (NASDAQ:IMUX) disclosed its financial results for the fourth quarter and year ended December 31, 2023, alongside significant clinical advancements, marking a pivotal

The journey toward effective therapies for patients with multiple sclerosis (MS) is marked by persistent challenges. Despite advancements in addressing relapses, the specter of disability progression

– Webcast to be Held at 8:00 am ET on February 22, 2024 – NEW YORK , Feb. 15, 2024 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of oral

Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof sheds light on her crucial role and the groundbreaking strides being made in the scientific world ahead of the International Day of Wo

Immunic Inc (NASDAQ:IMUX) shares took off after the biotechnology firm announced it would be raising up to $240 million in a private placement. Immunic stock was up 11.2% at US$1.58 before Friday's o

Immunic, Inc. said the US Patent and Trademark Office has given it a notice of allowance for patent application 17/992,162 entitled entitled 'Compounds and Dosage Regimen for Use in the Prevention o

Immunic, Inc. (NASDAQ:IMUX ) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Jessica Breu - Head of IR & Communications Dr. Daniel Vitt - CEO and President Glenn Wha

Immunic Inc (NASDAQ:IMUX) – a biotechnology company developing a pipeline of orally administered small molecule therapies for chronic inflammatory and autoimmune diseases - during the three months e

Immunic Inc (NASDAQ:IMUX) told investors it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application protecting the treatment of relapsing multiple sclerosis

Immunic Inc (NASDAQ:IMUX) announced that data from its Phase 2 EMPhASIS trial of nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in relapsing-remitting multiple sclerosis

Shares in Immunic Therapeutics Inc. soared 48% in after-hours trading following the release of encouraging interim data from its phase II CALLIPER trial assessing the potential of its treatment for�

NEW YORK , Sept. 6, 2023 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammat